Loss of imprinting of insulin-like growth factor 2 is associated with increased risk of lymph node metastasis and gastric corpus cancer

Table 3 Association of clinicopathological features with LIT1, AIGF2 and H19 LOI

	LIT1 LOI (+) N = 12	LIT1 LOI (--) N = 10	P-value	IGF2 LOI (+) N = 18	IGF2 LOI (--) N = 22	P-value	H19 LOI(+) N = 3	H19 LOI (--) N = 32	P-value
Tumor location			1.000			.028			.633
antrum,	10 (83.3%)	8 (80%)		10 (55.6%)	20 (90.9%)		3 (100%)	22 (68.8%)
gastric corpus,	2 (16.7%)	2 (10%)		8 (44.4%)	2 (9.1%)		0	10 (31.2%)
gastric cardia	0	0		0	0		0	0
Histological differentiation (well, mod/poor, muc)	5/7	4/6	1.000	9/9	10/12	.775	1/2	15/17	1.000
Lymph node metastasis	5 (41.7%)	4 (40%)	1.000	9 (50%)	4 (18.2%)	.033	1 (33.3%)	12 (37.5%)	1.000
Hepatic and peritoneal metastasis	1 (8.3%)	0	1.000	1 (5.6%)	1 (4.6%)	1.000	0	2 (6.25%)	1.000
Lymphatic invasion	4 (33.3%)	1 (10%)	.323	4 (22.2%)	4 (18.2%)	1.000	0	8 (25%)	.789
Venous invasion	1 (8.3%)	0	1.000	1 (5.6%)	1 (4.6%)	1.000	0	2 (6.25%)	1.000
Tumour Size			.746			.332			.423
<2 cm	0	0		3 (16.7%)	6 (27.3%)		0	6 (18.8%)
2--5 cm	8 (66.7%)	6 (60%)		7 (38.9%)	11 (50%)		1 (33.3%)	16 (50%)
>5 cm	4 (33.3%)	4 (40%)		8 (44.4%)	5 (22.7%)		2 (66.7%)	10 (31.3%)
TNM			.369			.525			.208
T+N+M=<3	7 (58.3%)	3 (30%)		8 (44.4%)	12 (54.6%)		0	18 (56.3%)
T+N+M>=4	5 (41.7%)	7 (70%)		10 (55.6%)	10 (45.4%)		3 (100%)	14 (43.7%)
Stage			1.000			1.000			1.000
early	1 (8.3%)	0		0	1 (4.6%)		0	1 (3.1%)
advanced	11 (91.7%)	10(100%)		18 (100%)	21 (95.4%)		3 (100%)	31 (96.9%)
Borrmann type			.620			.337			.753
I	1 (9.1%)	0		0	2 (9.5%)		0	2 (6.5%)
II	0	0		0	0		0	0
III	9 (81.8%)	9 (90%)		16 (88.9%)	18 (85.7%)		3 (100%)	26 (83.9%)
IV	1 (9.1%)	1(10%)		2 (11.1%)	1 (4.8%)		0	3 (9.7%)

ISSN: 1756-9966